

Press release

Servier Brings Together Renowned Scientific Experts and Showcases Therapeutic Innovation to Support the Fight against Cancer

- On June 18, 2024, THRPTX™, the Therapeutics Innovation Summit, the first scientific symposium organized by Servier, will bring together renowned international experts, researchers and scientists, including Professor William G. Kaelin Jr., 2019 Nobel Prize Winner in Physiology or Medicine, at the Servier Research and Development Institute in Paris-Saclay.
- This inaugural edition, focused on oncology, will cover patient expectations, scientific and therapeutic progress, as well as the socioeconomic stakes involved with research and development.
- Through THRPTX™, Servier is reaffirming its commitment to act as a catalyst for scientific excellence and drive therapeutic progress to serve patient needs.

Suresnes, May 28, 2024 - Servier, an independent global pharmaceutical group, will bring together the world's leading R&D leaders on June 18, 2024 at the Servier Research & Development Institute in the heart of the Paris-Saclay innovation hub, for a groundbreaking scientific event: THRPTX, the Therapeutics Innovation Summit. This inaugural event focused on oncology aligns with the Group's commitment to uniting the research ecosystem and acting as a catalyst for scientific excellence.

A groundbreaking event and a catalyst for scientific excellence to accelerate therapeutic innovation

For the first edition, the Therapeutics Innovation Summit (THRPTX for THeRaPeuTics) will bring together scientists, experts, doctors, researchers, decision-makers and informed observers to map out tomorrow's health. Servier aims to create a unique event during which all of these stakeholders can meet to take stock of the main therapeutic advances within oncology, while looking ahead to their potential repercussions on the health ecosystem.

The program includes two core components. During the first session, experts will present the challenges and stakes involved with science and medical innovation to serve patient needs, illustrated by examples of diagnosis, treatments and support for patients following their treatment. The second session will look at the links between medical innovation and our societies: what are society's expectations in terms of innovation in health, and how is innovation an aspect of medical practice? As an introduction to the symposium, Professor William G. Kaelin Jr., winner of the 2019 Nobel Prize in Physiology or Medicine, will deliver a keynote conference on his work, describing the role of oxygen in the cellular mechanisms of cancer. As a conclusion, he will also take part in an innovative "meeting of minds" with a doctoral student who will represent Servier's post-doctoral community, an original encounter in which an up-and-coming scientist will exchange views with a world-renowned researcher.

*"We designed the first edition of the THRPTX Innovation Summit as a real catalyst for scientific excellence, a place where experts, decisionmakers and recognized observers could come together to share their visions of tomorrow's health," said **Group President Olivier Laureau**, who will introduce the event. "By establishing a space for pioneering dialogue on science, our Group is proud to spotlight therapeutic innovations that will positively impact the health care ecosystem for patients and their families."*

By hosting the international THRPTX summit one year after it officially opened, the Servier Research and Development Institute in Paris-Saclay is affirming its position at the heart of the hub's technological ecosystem and its growing international reach. With a staff of 1,200 based in the facility, the Servier Research and Development Institute in Paris-Saclay represents an investment of nearly

€400 million, highlighting Servier's ambition to build open, dynamic, productive and innovative research in France to serve patients.

Oncology, the main theme of THRPTX, and at the heart of innovation at Servier

Each year, Servier dedicates 21.5% of its brand-name revenue to Research and Development and is an industry leader for R&D investment. This investment is made possible by the Group's governance structure, which ensures its strategic independence.

“With this first THRPTX event focused on oncology, we are proud to create a pioneering space for dialogue looking to share the therapeutic innovations that will help accelerate research and impact each individual's health by 2035. As an independent Group, developing ambitious and agile R&D to deliver long-term performance is crucial to enable new therapeutic advances in the future that will benefit cancer patients,” **said Claude Bertrand, Servier's Executive Vice President Research and Development and Chief Scientific Officer.**

With nearly 10 million deaths in 2022, cancer is the second leading cause of death worldwide according to the WHO. Faced with such staggering needs, Servier has made the strategic choice to focus its resources and efforts on the field of oncology, where needs are still unmet. The Group allocates over 70% of its R&D budget to oncology.

With 37 projects in clinical development and under research in this area, the Group has a promising pipeline in place with outstanding prospects for innovation, particularly for rare and hard-to-treat cancers for which patients do not have any or have only limited therapeutic alternatives, with differentiation angles. These include digestive cancers (gastric cancer, pancreatic cancer, cholangiocarcinoma, or rare and aggressive bile duct cancer), gliomas (or brain tumors), blood cancers (acute myeloid leukemia, acute lymphoblastic leukemia, lymphomas) and pediatric cancers. Servier's R&D programs are focused on two approaches: immuno-oncology and targeted therapies. The Group aims to develop new therapeutic options for patients so that as many people as possible can benefit from them.

Open innovation, driving therapeutic progress for patients

An interdisciplinary approach and collaboration are key features of Servier's strategy to make R&D more agile. By pooling expertise and capitalizing on the complementary positioning of the various health stakeholders, Servier believes that science will progress more quickly and research will have greater chances of success. Collaborations with start-ups, academic partnerships, cooperations with other pharmaceutical companies, from fundamental research to clinical trials and even the technological or industrial development of products: with over 70 scientific partnerships and collaborations worldwide, Servier has made open innovation the driving force for the discovery and development of new medicines and solutions to serve patient needs.

“With this event, a groundbreaking step for Servier, we want to help bring together and promote dialogue between the best representatives of scientific excellence and innovation! By leading medical innovation with patients and our partners, we will be able to meet tomorrow's health challenges. We are therefore stronger together, and through its dynamic collaborative approach, THRPTX will be a concrete example of this! This event also reflects a Group that is open to the outside world, that works in cooperation with its ecosystem and shares knowledge with a view to identifying the constraints and current challenges for medical innovation, as well as to anticipating the medical solutions for tomorrow's world,” **said Arnaud Lallouette, Servier's Executive Vice President Global Medical & Patient Affairs.**

To learn more about THRPTX, Servier's Therapeutics Innovation Summit, visit the dedicated website: <https://servier.com/en/newsroom/thrptx-innovation-summit-symposium>

Press contacts

Servier

Marion Breyer marion.breyer@servier.com
Presse@servier.com

Havas Red Health

Juliette Arcos-Desloges
juliette.desloges@havasred.com
Claire Olivieri
claire.olivieri-ringot@havasred.com

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)